Hematopoiesis News Volume 1.03 | Feb 2 2010

Blood Will Tell Old Stem Cells How to Act Young
Scientists have demonstrated that in old mice exposed to certain proteins that are present in blood from young mice, old blood stem cells begin to act like young ones, and this process is driven by signals from another type of cell nearby in the bone. [Press release from the Joslin Diabetes Center discussing online prepublication in Nature]

Fat Tissue May Be a Source of Valuable Blood Stem Cells
Results provide compelling evidence that the stromal vascular fraction derived from adipose tissue contains functional hematopoietic stem and progenitor cells capable of generating hematopoietic cells. [Press release from The American Society of Hematology discussing online prepublication in Blood]

St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project
St. Jude Children’s Research Hospital and Washington University School of Medicine in St. Louis, announced an unprecedented effort to identify the genetic changes that give rise to some of the world’s deadliest childhood cancers. [St. Jude Children’s Research Hospital Press Release]

Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express by STEMCELL Technologies     REQUEST A SAMPLE

LABORATORY RESEARCH

Systemic Signals Regulate Ageing and Rejuvenation of Blood Stem Cell Niches
Scientists show that age-associated changes in stem cell supportive niche cells deregulate normal hematopoiesis by causing hematopoietic stem cell dysfunction. [Nature]

Gli1 Regulates the Proliferation and Differentiation of Hematopoietic Stem Cells and Myeloid Progenitors
Researchers have analyzed hematopoietic stem cell (HSC) and progenitor function in mice with a homozygous deletion of Gli1 (Gli1null). Gli1null mice have more long-term HSC that are more quiescent and show increased engraftment after transplantation. [Blood]

Notch Signaling Distinguishes Two Waves of Definitive Hematopoiesis in the Zebrafish Embryo
Scientists examine whether embryonic specification of erythromyeloid progenitors requires Notch signaling as has been shown for hematopoietic stem cells. [Blood]

Expression Map of the Human Exome in CD34+ Cells and Blood Cells: Increased Alternative Splicing in Cell Motility and Immune Response Genes
Using Human Exon ST 1.0 microarrays, the entire exome expression profile of immature CD34+ hematopoietic stem and progenitor cells and mature whole blood cells was mapped, compared to a collection of solid tissues and made freely available as an online exome expression atlas. [PLoS ONE]

RAD 001 (Everolimus) Prevents mTOR and Akt Late Re-Activation in Response to Imatinib in Chronic Myeloid Leukemia
The rapamycin derivative RAD 001 (everolimus, Novartis Institutes for Biomedical Research) inhibits mammalian target of rapamycin (mTOR) and, more importantly, revokes mTOR late re-activation in response to imatinib mesylate. [J Cell Biochem]

Chemotherapy-Induced Mesenchymal Stem Cell Damage in Patients with Hematological Malignancy
The phenotype and functional properties of marrow mesenchymal stem cells derived from untreated and chemotherapeutically treated patients with hematological malignancy were compared. [Ann Hematol]

CLINICAL RESEARCH

Gemtuzumab Ozogamicin as Postremission Treatment in Acute Myeloid Leukemia at 60 Years of Age or More: Results of a Multicenter Phase III Study
Postremission treatment with gemtuzumab ozogamicin in acute myeloid leukemia at older age does not provide benefits regarding any of the clinical endpoints. [Blood]

Investigation of Murine Spleen as a Niche for Hematopoiesis
The presence of endogenous hematopoietic progenitors in spleen was investigated by transplanting intact spleen into allotype-distinct recipients and monitoring development of progeny cells in grafted tissues. [Transplantation]

Column-Free Isolation of Hematopoietic Stem and Progenitor Cells with EasySep®     REQUEST A SAMPLE

Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Acting Hemophilia B Therapy
Biogen Idec and Swedish Orphan Biovitrum announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein in hemophilia B patients. [Biogen Idec Press Release]

Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukemia
GlaxoSmithKline and Genmab A/S announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Arzerra (ofatumumab) for the treatment of refractory chronic lymphocytic leukemia. [GlaxoSmithKline Press Release]

Food and Drug Agency Grants Orphan Drug Designation to GRASPA® for Treatment of Acute Lymphoblastic Leukemia
ERYtech Pharma announces that Food and Drug Agency has granted an Orphan Drug Designation for GRASPA®, the company’s lead product in acute lymphoblastic leukemia. [ERYtech Pharma Press Release]

Notice of Availability of Administrative Supplements for R25 Science Education Grants (NOT-DA-10-007) [National Institutes of Health, United States]

Recovery Act Limited Competition: Program to Enhance NIH-supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001) [National Institutes of Health, United States]

Notice of Intent to Publish a Request for Applications for NHLBI Research Centers at Minority-Serving Institutions (P30) (NOT-HL-11-150) [National Heart, Lung, and Blood Institute, United States]

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Heart, Lung, and Blood Institute, United States]

Public Consultation (MLX 366): Intention to Amend the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008 (SI 2008/1692) [The Medicines and Healthcare products Regulatory Agency, United Kingdom]

2010 Bone Marrow Transplant (BMT) Tandem Meetings
February 24-28, 2010
Orlando, United States

36th Annual Meeting of the European Group for Blood & Marrow Transplantation (EBMT)
March 21-24, 2010
Vienna, Austria

12th Biennial Canadian Blood and Marrow Transplant Group (CBMTG) Conference
April 7-10, 2010
Vancouver, Canada

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!